Clinical Trials · NCT02837783

A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)

TerminatedPhase 4Linaclotide (Prohibited)
Phase
Phase 4
Recruitment status
Terminated
Sponsor
Ironwood Pharmaceuticals, Inc.
Enrollment
20
Start date
Dec 2016
Locations
1 site, United Kingdom
Primary endpoint
Change From Baseline in Abdominal Girth at Week 4
View Linaclotide compound reference